NTRK3 and cancer: IHC provides a useful screening technique to identify tumors with potential NTRK gene fusions that warrant further confirmation with NGS or other robust techniques, but there is a need to overcome the lack of sensitivity to detect fusions involving NTRK3. NTRK gene fusions have been identified in a broad range of cancers and appear to be tumor agnostic driver events.